This is a correction to: Peter Rossing, Florian M. M. Baeres, George Bakris, Heidrun Bosch-Traberg, Mette Gislum, Stephen C. L. Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F. E. Mann, Henriette Mersebach, Vlado Perkovic, Katherine Tuttle, Richard Pratley, on behalf of the FLOW Steering Committee and FLOW Trial Investigators, The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease, Nephrology Dialysis Transplantation, Volume 38, Issue 9, September 2023, Pages 2041–2051, https://doi.org/10.1093/ndt/gfad009
In the originally published version of this manuscript, the following sentence required correction:
‘Both guidelines also recommend a non-steroidal mineralocorticoid receptor antagonist (finerenone) for patients with CKD at increased risk for CV events but unable to use SGLT2is [4, 5].’
This sentence has been corrected online to read as follows:
‘Both guidelines also recommend a non-steroidal mineralocorticoid receptor antagonist (finerenone) for patients with CKD at increased risk for CV events, or CKD progression, or unable to use SGLT2is [4,5].’
In addition, in the originally published supplementary data file, Figure S1 was omitted in error. The supplementary data file has now been updated to a correct version which includes this figure.